F Goubin

793 total citations
10 papers, 679 citations indexed

About

F Goubin is a scholar working on Oncology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, F Goubin has authored 10 papers receiving a total of 679 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Molecular Biology and 2 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in F Goubin's work include Cancer-related Molecular Pathways (4 papers), Drug Transport and Resistance Mechanisms (3 papers) and RNA modifications and cancer (2 papers). F Goubin is often cited by papers focused on Cancer-related Molecular Pathways (4 papers), Drug Transport and Resistance Mechanisms (3 papers) and RNA modifications and cancer (2 papers). F Goubin collaborates with scholars based in France, Switzerland and Italy. F Goubin's co-authors include Bernard Ducommun, Marta Molinari, Giulio Draetta, Ciro Mercurio, Vladimir N. Podust, Larissa M. Podust, Jean‐Denis Bailly, Catherine Müller, Valérie Mils and Véronique Baldin and has published in prestigious journals such as Biochemistry, Oncogene and FEBS Letters.

In The Last Decade

F Goubin

10 papers receiving 673 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F Goubin France	9	570	366	143	48	34	10	679
Satadal Chatterjee United States	14	506 0.9×	360 1.0×	62 0.4×	60 1.3×	12 0.4×	23	656
T. Tsuruo Japan	10	255 0.4×	290 0.8×	32 0.2×	35 0.7×	19 0.6×	14	504
Michelle A. Herrmann United States	11	283 0.5×	156 0.4×	37 0.3×	67 1.4×	29 0.9×	17	488
Ju-Hwa Kim South Korea	13	295 0.5×	239 0.7×	22 0.2×	53 1.1×	13 0.4×	14	448
Parviz Behnam‐Motlagh Sweden	13	239 0.4×	101 0.3×	50 0.3×	50 1.0×	30 0.9×	23	423
R Zhang United States	9	524 0.9×	230 0.6×	41 0.3×	56 1.2×	26 0.8×	14	612
David J. Villeneuve Canada	10	246 0.4×	175 0.5×	54 0.4×	79 1.6×	5 0.1×	12	372
Takashi Tsuruo Japan	11	349 0.6×	313 0.9×	44 0.3×	30 0.6×	4 0.1×	16	532
Mary Gleason-Guzman United States	13	589 1.0×	233 0.6×	16 0.1×	53 1.1×	10 0.3×	15	813
Jonathan J. Lyon United Kingdom	9	328 0.6×	158 0.4×	55 0.4×	82 1.7×	21 0.6×	16	517

Countries citing papers authored by F Goubin

Since Specialization

Citations

This map shows the geographic impact of F Goubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F Goubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F Goubin more than expected).

Fields of papers citing papers by F Goubin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F Goubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F Goubin. The network helps show where F Goubin may publish in the future.

Co-authorship network of co-authors of F Goubin

This figure shows the co-authorship network connecting the top 25 collaborators of F Goubin. A scholar is included among the top collaborators of F Goubin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F Goubin. F Goubin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Prévost, Grégoire, Marie-Christine Brézak, F Goubin, et al.. (2003). Inhibitors of the CDC25 phosphatases.. PubMed. 5. 225–34. 26 indexed citations

Molinari, Marta, et al.. (2000). Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Reports. 1(1). 71–79. 161 indexed citations

Mils, Valérie, Véronique Baldin, F Goubin, et al.. (2000). Specific interaction between 14-3-3 isoforms and the human CDC25B phosphatase. Oncogene. 19(10). 1257–1265. 85 indexed citations

Knibiehler, Martine, F Goubin, Nathalie Escalas, et al.. (1996). Interaction studies between the p21Cip1/Waf1 cyclin‐dependent kinase inhibitor and proliferating cell nuclear antigen (PCNA) by surface plasmo resonance. FEBS Letters. 391(1-2). 66–70. 24 indexed citations

Tournier, Sylvie, et al.. (1996). Heterologous expression of the human cyclin-dependent kinase inhibitor p21Cip1 in the fission yeast, Schizosaccharomyces pombe reveals a role for PCNA in the chk1+ cell cycle checkpoint pathway.. Molecular Biology of the Cell. 7(4). 651–662. 28 indexed citations

Podust, Vladimir N., et al.. (1995). Mechanism of Inhibition of Proliferating Cell Nuclear Antigen-Dependent DNA Synthesis by the Cyclin-Dependent Kinase Inhibitor p21. Biochemistry. 34(27). 8869–8875. 108 indexed citations

Müller, Catherine, F Goubin, Eric Ferrandis, et al.. (1995). Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells.. Molecular Pharmacology. 47(1). 51–56. 63 indexed citations

Goubin, F & Bernard Ducommun. (1995). Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor.. PubMed. 10(12). 2281–7. 108 indexed citations

Müller, Catherine, Jean‐Denis Bailly, F Goubin, et al.. (1994). Verapamil decreases P‐glycoprotein expression in multidrug‐resistant human leukemic cell lines. International Journal of Cancer. 56(5). 749–754. 69 indexed citations

10.

Muller, Christian D., Jean‐Denis Bailly, J P Jaffrézou, F Goubin, & G Laurent. (1994). [Pharmacological control of P-glycoprotein expression].. PubMed. 81(5). 386–91. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact